Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report

Kristin Weiss; Obafunbi Abimbola; Kelsey Miller; William Y Kim; Tracy L Rose; Marc A Bjurlin; Kathryn H Gessner

doi:10.1016/j.urology.2023.11.019

Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report

Urology. 2024 Feb:184:75-78. doi: 10.1016/j.urology.2023.11.019. Epub 2023 Dec 3.

Authors

Kristin Weiss¹, Obafunbi Abimbola², Kelsey Miller³, William Y Kim⁴, Tracy L Rose⁵, Marc A Bjurlin⁶, Kathryn H Gessner⁷

Affiliations

¹ University of North Carolina School of Medicine, Chapel Hill, NC.
² Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
³ Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
⁴ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
⁵ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
⁶ Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
⁷ Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: Kathryn_gessner@unchealth.unc.edu.

PMID: 38052324
DOI: 10.1016/j.urology.2023.11.019

Abstract

In bladder urothelial carcinoma, ERBB2 mutations have been associated with favorable response to platinum-based neoadjuvant chemotherapy. However, this association has not been reported in upper tract urothelial carcinoma (UTUC). We describe an excellent response to cisplatin-based chemotherapy in metastatic UTUC with an ERBB2 mutation. Our patient is a 54-year-old female with metastatic UTUC who received systemic cisplatin and gemcitabine. Postchemotherapy imaging demonstrated decreased size of pyelocaliceal mass and decreased retroperitoneal adenopathy compared to initial imaging. Surgical pathology from consolidative resection showed 3 mm residual renal tumor and no viable lymph node disease. Genomic testing demonstrated an ERBB2 gain of function mutation.

Publication types

Case Reports

MeSH terms

Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / genetics
Cisplatin / therapeutic use
Female
Genes, erbB-2
Humans
Middle Aged
Mutation
Neoplasm, Residual
Pathologic Complete Response
Platinum
Receptor, ErbB-2 / genetics
Urinary Bladder Neoplasms*

Substances

Platinum
Cisplatin
ERBB2 protein, human
Receptor, ErbB-2